It has been established in early research that DMT has a neuroplastic effect on the brain, which means it creates new connections with neurons. Neurogenesis is a very important process that needs to happen after an injury.
Algernon Pharmaceuticals (CSE: AGN) is preparing to launch a Phase 1 study of DMT for the treatment of stroke.
There are surprisingly few stroke treatments available on the market today, which is why we are very bullish on AGN, especially at this current market cap.
AGN has a low share count and a tight share structure. There are strong investors behind this company including AlphaNorth Asset Management, which increased its AGN stake yesterday to more than 13%.
AGN is awaiting approval to be listed on the NASDAQ.
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from AGN of US$100,000 cash for a twelve-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.